Yan Ming 4

What Happened

• Yan Ming, Chief Technology Officer and a director of Cytek Biosciences (CTKB), had multiple Restricted Stock Units (RSUs) convert into common stock on May 18, 2026. A total of 22,179 shares were issued on conversion. To satisfy tax-withholding obligations, 5,532 shares were surrendered to the company (share withholding) at an effective withholding value of $3.55 per share, totaling $19,638. The result was a net delivery of 16,647 shares to Yan Ming.
• The Form 4 records the RSU conversions as derivative-to-stock transactions (code M) and the withholding as tax withholding (code F). The $0.00 disposals shown for the derivative entries reflect the conversion of the RSU awards rather than an open-market sale.

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (appears timely).
• Gross shares converted: 22,179; Shares withheld for taxes: 5,532; Net shares delivered: 16,647.
• Withholding price/value: $3.55 per share; total withholding value ≈ $19,638.
• Transaction codes: M = exercise/conversion of derivative (RSU conversion); F = payment of tax liability via share surrender.
• Footnotes: RSUs represent contingent rights to one share each; vesting schedules noted in filing indicate multi-year staggered vesting (see filing footnotes). Footnote F2 confirms shares were surrendered to satisfy tax withholding.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This was not an open-market sale or purchase but routine RSU vesting with share withholding to cover taxes (a common, administrative transaction). Such withholding transactions typically do not signal a change in insider sentiment the way open-market buys or sales might.
• For retail investors: conversions/vestings increase insider stock holdings on a paper basis (minus withheld shares). The filing shows standard RSU vesting mechanics rather than active trading by the insider.